FibroBiologics (FBLG) Other Non Operating Income (2023 - 2026)
FibroBiologics (FBLG) posted quarterly Other Non Operating Income of -$92000.0 for Q2 2026, up 85.28% year-over-year from -$49654.6 in Q2 2025, and down 4500.0% on a QoQ basis from -$2000.0 in Q1 2026.
FibroBiologics (FBLG) Other Non Operating Income (2023 - 2026) Analysis & Trends
FibroBiologics has reported Other Non Operating Income for 4 years, with the latest figure at -$92000.0 in Q2 2026.
- Other Non Operating Income for Q2 2026 came in at -$92000.0, up 85.28% year-over-year; the trailing twelve-month figure through Jun 2026 was -$1.8 million (down 29266.67% YoY), and the FY2025 annual result was -$1.8 million, down 325.18% from the prior year.
- Other Non Operating Income slipped to -$92000.0 in Q2 2026, from -$2000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $849000.0 in Q3 2024 and troughed at -$846000.0 in Q3 2025.
- A 4-year average of -$173818.2 and a median of -$92000.0 in 2026 frame the typical range for Other Non Operating Income.
- The widest annual swing landed in 2024, when Other Non Operating Income surged 702.13%; it then sank 2183.33% in 2025.
- A 4-year view of Other Non Operating Income shows it stood at -$141000.0 in 2023, then surged by 265.25% to $233000.0 in 2024, then sank by 447.64% to -$810000.0 in 2025, then soared by 88.64% to -$92000.0 in 2026.
- Per Business Quant data, the three most recent Other Non Operating Income figures were -$92000.0 in Q2 2026, -$2000.0 in Q1 2026, and -$810000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -92,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | 625,000.00 |
| Sep 30, 2025 | -846,000.00 |
| Jun 30, 2025 | 334,000.00 |
| Mar 31, 2025 | -451,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Sep 30, 2023 | -141,000.00 |
| Jun 30, 2023 | -57,000.00 |